Granted Patent B2

US 12,419,917 · App. 17/725,377 · Granted Sep 23, 2025

Inventors: Gavin Mark Gear (Monterey, CA); Roger Brett Edmonds (Auckland, NZ)

Assignee: NDAL MFG INC

A61K35/644A61K47/10A61K47/12A61K47/22A61P31/00

Abstract

Claims (20)

1. A method of treating a human suffering from an infection or disease caused by a pathogen, the method comprising:

administering to the human in need thereof a therapeutically effective amount of a composition comprising a fractionated honey,

wherein the fractionated honey is Leptospermum scoparium honey and is free of all DNA markers for Leptospermum scoparium pollen;

wherein the fractionated honey does not undergo yeast fermentation associated with honey at moisture contents greater than 19% water by weight; and

wherein the composition comprises between 19 weight % and 99 weight % water, and has a water activity of between 0.85 and 1.0, and a pH between 3 and 4.5.

2. The method of claim 1 wherein the infection comprises a lung, a nasal or a sinus infection, and the composition is administered in the form of a spray via an intranasal or an oral route.

3. The method of claim 1 wherein the infection is caused by a gram positive bacterium, a gram negative bacterium or a virus.

4. The method of claim 1 wherein the infection is caused by a bacterium selected from the group consisting of Staphylococcus aureus, Haemophilus influenza, Pseudomonas aeruginosa, Staphylococcus epidermidis, Propionibacterium acnes , coagulase negative Staphylococcus, Streptococcus pneumoniae, Prevotella Streptococcus, Veillonella, Proteus mirabilis, Klebsiella pneumonia, Pneumocystis carinii , cytomegalovirus, methicillin-resistant Staphylococcus aureus (MRSA), Acinetobacter baumannii, chlamydophila pneumonia or Mycoplasma pneumoniae.

5. The method of claim 1 wherein the infection is caused by a virus selected from the group consisting of severe acute respiratory syndrome coronavirus (SARS-COV), sever acute respiratory syndrome coronavirus 2 (SARS-COV- 2 ), COVID-19, Middle East respiratory syndrome coronavirus (MERS-COV), respiratory syncytial virus (RSV), Rhinoviruses, Parainfluenza viruses, Influenza viruses, and Adenoviruses.

6. The method of claim 1 wherein the composition comprises the fractionated honey in an amount of from 4 weight % to 80 weight % of the composition, and further comprises water in an amount of 50 weight % to 82 weight %, glycerin in an amount of 5 weight % to 10 weight %, and an acid mixture in an amount of 1 weight % to 3 weight %.

7. The method of claim 6 wherein the acid mixture comprises citric acid and ascorbic acid in amounts sufficient to prevent fermentation of the composition.

8. The method of claim 1 wherein the composition is free of a chemical preservative.

9. The method of claim 1 wherein the fractionated honey comprises methylglyoxal in an amount of at least 83 mg/kg.

10. The method of claim 1 wherein the fractionated honey comprises methylglyoxal in an amount of at least 573 mg/kg.

11. A method of preventing an infection in a human caused by a pathogen, the method comprising:

administering to the human in need thereof a therapeutically effective amount of a composition comprising a fractionated honey,

wherein the fractionated honey is Leptospermum scoparium honey and is free of all DNA markers for Leptospermum scoparium pollen;

wherein the fractionated honey does not undergo yeast fermentation associated with honey at moisture contents greater than 19% water by weight;

wherein the composition comprises between 19 weight % and 99 weight % water, and has a water activity of between 0.85 and 1.0, a pH between 3 and 4.5; and

wherein the infection comprises nonallergic forms of perennial rhinitis including infectious, vasomotor, drug-induced or atrophic rhinitis, or the infection comprises rhinitis medicamentosa.

Assignments (1)

Continuity (3)

References Cited (121)